Immunosuppressive drugs and novel strategies to prevent acute and chronic allograft rejection

Seminars in Respiratory and Critical Care Medicine

Volumn 22, Issue 5, 2001, Pages 559-580

  Lake, K D ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Immunosuppressants for lung transplantation; Rejection therapy; Treatment of obliterative bronchiolitis

Indexed keywords

ACICLOVIR; ALLOPURINOL; ANTACID AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; IRON; MACROLIDE; MAGNESIUM; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; PROBENECID; RAPAMYCIN; RIFAMPICIN; TACROLIMUS; THYMOCYTE ANTIBODY;

DIARRHEA; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FEVER; GRAFT REJECTION; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPERICUM PERFORATUM; HYPERTENSION; LEUKOPENIA; LYMPH NODE IRRADIATION; NEPHROTOXICITY; PRIORITY JOURNAL; PUVA; REVIEW; TREMOR;

EID: 0035190033     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18428     Document Type: Review

References (179)

1. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
2. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
3. A blinded, randomized clinical trial of my-cophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
4. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study
5. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients
6. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin2-receptor monoclonal antibody
7. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation
8. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients
9. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation
10. Daclizumab: Outcome of phase III trials and mechanism of action
11. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation
12. One-year analysis of an ongoing international randomized study of mycophenolate mofetil (MMF) vs azathioprine (AZA) in lung transplantation
13. Clinical trial of tacrolimus versus cyclosporine in lung transplantation
14. Tacrolimus versus cyclosporine after lung transplantation: A prospective, open, randomized two-center trial comparing two different immunosuppressive protocols
15. The Registry of the International Society for Heart and Lung Transplantation: Seventeenth official report - 2000
16. Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts
17. Worldwide Thoracic Organ Transplantation: A report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation
18. Cyclosporine
19. Mechanisms of action of cyclosporine
20. Cyclosporin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders
21. Reduced inter- and intra-subject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals
22. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: Lack of prediction by the erythromycin breath test
23. Drug metabolism by cytochromes P450 in the liver and small bowel
24. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver: cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine
25. Identification of a polymorphically expressed member of the human cytochrome P-450III family
26. Identification of an inducible form of cytochrome P-450 in human liver
27. First-pass metabolism of cyclosporin by the gut
28. Expression of P450IIIA4 in duodenal mucosa: Interpatient variability and regulation in cultured explants
29. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
30. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells
31. Detection of P-glycoprotein with four monoclonal antibodies in normal and tumor tissues
32. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group
33. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: Its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation
34. Is 3-hour cyclosporine blood level superior to trough level in early postrenal transplantation period?
35. Pharmacokinetics of a new oral formulation of cyclosporine in liver transplant recipients
36. Therapeutic drug monitoring of cyclosporine and tacrolimus: Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus
37. Important interactions of drugs with immunosuppressive agents used in transplant recipients
38. Clinically significant drug interactions with new immunosuppressive agents
39. Drug interaction of St John's wort with cyclosporin
40. Acute heart transplant rejection due to Saint John's wort
41. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction
42. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine
43. Cyclosporin-erythromycin interaction in renal transplant patients
44. Decrease in a constitutive form of cytochrome P-450 by macrolide antibiotics
45. Cost containment: Coadministration of diltiazem with cyclosporine after heart transplantation
46. Diltiazem and economic use of cyclosporin
47. Cyclosporin-diltiazem interaction
48. Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients
49. Verapamil inhibits cyclosporin metabolism
50. The effects of calcium channel blockers on cyclosporine and its metabolites in renal transplant recipients
51. Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine
52. Recommendations for bioequivalence testing of cyclosporine generics revisited
53. Renal complications after heart transplantation
54. Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future
55. Risk factors for chronic renal dysfunction in cardiac allograft recipients
56. Treatment of endstage renal failure after heart transplantation
57. Hyperlipidemia in solid organ transplantation
58. Role of cyclosporine in inducing hyperuricemia in heart transplant patients
59. Hypertension in transplant recipients
60. Renal failure in the recipients of nonrenal solid organ trasplants
61. Tacrolimus in solid organ transplantation: An update
62. Tacrolimus: A further update of its pharmacology and therapeutic use in the management of organ transplantation
63. Differential effects of cyclosporin A and tacrolimus on the production of TGF-beta: Implications for the development of obliterative bronchiolitis after lung transplantation
64. Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants
65. TGF-beta expression in renal transplant biopsies: A comparative study between cyclosporin-A and tacrolimus
66. Measurement of FK 506 by HPLC and isolation and characterization of its metabolites
67. High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile, and urine of liver grafted patients
68. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone
69. Clinical pharmacokinetics of tacrolimus
70. Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients
71. Immunosuppressive agents in organ transplantation: Past, present, and future
72. Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients: Importance of trough level as a practical indicator
73. Pharma-cokinetics of tacrolimus in liver transplant patients
74. Clinical pharma-cokinetics of tacrolimus in heart transplant recipients
75. Tacrolimus pharmaco-kinetics in BMT patients
76. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: A report of the United States Multicenter FK506 Kidney Transplant Group
77. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole
78. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients
79. Interactions between tacrolimus and antimicrobial agents
80. Herb-drug interactions
81. Higher immunosuppressive efficacy of mycophenolate mofetil in combination with FK 506 than in combination with cyclosporine A
82. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: A cross-sectional study
83. Coadministration of tacrolimus (FK) and mycophenolate mofetil (MMF) does not increase mycophenolic acid (MPA) exposure, but coadministration of cyclosporine (CsA) and MMF inhibits the enterohepatic recirculation of MPA, thereby decreasing its exposure
84. Pharmacokinetics (PK) and tolerability of tacrolimus and sirolimus combination therapy in stable renal transplant recipients
85. Minimizing cyclosporine concentration variability to optimize transplant outcome
86. The nephrotoxicity of immunosuppressive drugs
87. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection
88. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil vs. cyclosporine (Neoral) with mycophenolate mofetil after kidney transplantation
89. A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: Intermediate-term results
90. Tacrolimus: A superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation
91. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: Decreased hyperlipidemia and hypertension with tacrolimus
92. European Multicenter Tacrolimus (FK506) Heart Pilot study: One-year results - European Tacrolimus Multicenter Heart Study Group
93. Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation
94. Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome
95. FK 506 'rescue' immunosuppression for obliterative bronchiolitis after lung transplantation
96. The therapeutic use of azathioprine in renal transplantation
97. Quantitation of plasma azathioprine and 6-mercaptopurine levels in renal transplant patients
98. Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients
99. Azathioprine metabolism in kidney transplant recipients
100. Azathioprine metabolism: Pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients
101. Human kidney thiopurine methyltransferase: Purification and biochemical properties
102. Mercaptopurine pharmaco-genetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity
103. Human liver thiopurine methyltransferase pharmaco-genetics: Biochemical properties, liver-erythrocyte correlation and presence of isozymes
104. Azathioprine and allopurinol: The price of an avoidable drug interaction
105. Interaction of allopurinol with 6-mercaptopurine and azathioprine
106. Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine (NSC 755) in cancer patients
107. Severe megaloblastic anaemia associated with abnormal azathioprine metabolism
108. Alopecia as a consequence of tacrolimus therapy
109. Two cases of tacrolimus-induced alopecia following kidney transplantation
110. Mycophenolate mofetil
111. Mycophenolate mofetil: A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation
112. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients
113. Reduced mycophenolic acid concentrations are associated with an increased risk of rejection following heart transplantation
114. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: Importance of mycophenolic acid therapeutic drug monitoring
115. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients
116. Impairment of mycophenolate mofetil absorption by iron ion
117. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy and analogous in vitro findings
118. Clinical pharma-cokinetics of mycophenolate mofetil
119. The effect of renal insufficiency on mycophenolic acid protein binding
120. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: Results at three years
121. Mycophenolate mofetil (MMF) in heart transplantation: Rejection prevention and treatment
122. Mycophenolate mofetil (RS-61443): Preclinical, clinical, and three-year experience in heart transplantation
123. Treatment of recurrent heart rejection with mycophenolate mofetil (RS61443): Initial clinical experience
124. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients
125. Mycophenolate mofetil compared to azathioprine improves survival in patients surviving the initial cardiac transplant hospitalization: An analysis of the joint ISHLT/UNOS Thoracic Registry
126. Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: Preliminary experience
127. Mycophenolate mofetil in lung transplantation
128. Preliminary experience with mycophenolate mofetil used after lung transplantation
129. Salvage therapy with mycophenolate mofetil for lung transplant bronchiolitis obliterans: Importance of dosage
130. A case report of a double-blind, randomized trial of inhaled steroids in a patient with lung transplant bronchiolitis obliterans
131. Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation
132. Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation
133. Withdrawal of immunosuppression: Implications for composite tissue allograft transplantation
134. Bone loss after kidney transplantation: A longitudinal study in 115 graft recipients
135. Bone loss and turnover after cardiac transplantation
136. Immunosuppressant induced metabolic toxicities
137. Sirolimus: Continuing the evolution of transplant immunosuppression
138. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration
139. Pharmacokinetics of rapamycin
140. Historic landmarks in clinical transplantation: Conclusions from the consensus conference at the University of California, Los Angeles
141. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharma-cokinetics of each agent
142. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients
143. Bronchiolitis obliterans and organizing pneumonia in renal transplantation recipients
144. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients
145. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
146. RAD in stable lung and heart/lung transplant recipients: Safety, tolerability, pharmacokinetics, and impact of cystic fibrosis
147. Rapamycin inhibits development of obliterative airway disease in a murine heterotopic airway transplant model
148. Obliterative airway disease after heterotopic tracheal xenotransplantation: Pathogenesis and prevention using new immunosuppressive agents
149. Muromonab-CD3 and antithymocyte globulin in renal transplantation
150. Antibody response to OKT3 and methods for monitoring
151. In vivo cell activation following OKT3 administration: Systemic cytokine release and modulation by corticosteroids
152. Muromonab CD3. A review of its pharmacology and therapeutic potential
153. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients
154. Lung transplantation without the use of antilymphocyte antibody preparations
155. Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation: A plea for multicenter immunosuppressive trials
156. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3
157. Cytolytic therapy for the treatment of bronchiolitis obliterans syndrome following lung transplantation
158. Cytolytic therapy for the bronchiolitis obliterans syndrome complicating lung transplantation
159. Basiliximab
160. Daclizumab: A review of its use in the prevention of acute rejection in renal transplant recipients
161. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients
162. The efficacy of daclizumab, an anti-interleukin receptor antibody, in the prevention of acute rejection in lung transplantation
163. Preliminary data regarding the use of interleukin-2-receptor antibody (Daclizumab) in lung transplantation
164. Effects of inhaled nebulized steroids (budesonide) on acute and chronic lung function in heart-lung transplant patients
165. Delivery and distribution of aerosolized cyclosporine in lung allograft recipients
166. Aerosolized cyclosporine in lung recipients with refractory chronic rejection
167. Efficacy of inhaled cyclosporine in lung transplant recipients with refractory rejection: Correlation of intragraft cytokine gene expression with pulmonary function and histologic characteristics
168. Dose-related reversal of acute lung rejection by aerosolized cyclosporine
169. Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients
170. Methotrexate for lung transplant recipients with steroid-resistant acute rejection
171. Methotrexate can halt the progression of bronchiolitis obliterans syndrome in lung transplant recipients
172. Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation
173. Efficacy of total lymphoid irradiation for chronic allograft rejection following bilateral lung transplantation
174. Traitement du rejet de greffe d'organe par photochimiotherapie extracorporelle
175. Extracorporeal photochemotherapy treatment for acute lung rejection episode
176. Photopheresis for chronic rejection of lung transplant in a small pediatric patient
177. Photopheresis for chronic rejection of lung allografts
178. The impact of cytolytic therapy on bronchiolitis obliterans syndrome